Combogesic Iv Injection
NDC Package 0143-9150-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Combogesic Iv (acetaminophen and ibuprofen injection) injection is cOMBOGESIC IV is indicated in adults where an intravenous route of administration is considered clinically necessary for: • the relief of mild to moderate pain • the management of moderate to severe pain as an adjunct to opioid analgesicsLimitations of Use COMBOGESIC IV is indicated for short-term use of five days or less. This formulation utilizes a injection delivery system. Marketed by Hikma Pharmaceuticals Usa Inc., this product is identified by NDC 0143-9150 and is authorized under FDA application NDA215320.

Identification & Billing

NDC Package Code
0143-9150-10
Package Description
10 VIAL in 1 CARTON / 100 mL in 1 VIAL (0143-9150-01)
Product Code
0143-9150
11-Digit Billing Format
00143915010
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2673874 - acetaminophen 1000 MG / ibuprofen 300 MG in 100 ML Injection
  • RxCUI: 2673874 - 100 ML acetaminophen 10 MG/ML / ibuprofen 3 MG/ML Injection
  • RxCUI: 2673874 - 100 ML APAP 10 MG/ML / ibuprofen 3 MG/ML Injection
  • RxCUI: 2673874 - acetaminophen 1000 MG / ibuprofen 300 MG per 100 ML Injection
  • RxCUI: 2673880 - combogesic IV 1000 MG / 300 MG in 100 ML Injection

Clinical Specifications

Proprietary Name
Combogesic Iv
Non-Proprietary Name
Acetaminophen And Ibuprofen Injection
Substance Name
Acetaminophen; Ibuprofen
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
COMBOGESIC IV is indicated in adults where an intravenous route of administration is considered clinically necessary for: • the relief of mild to moderate pain • the management of moderate to severe pain as an adjunct to opioid analgesicsLimitations of Use COMBOGESIC IV is indicated for short-term use of five days or less.

Regulatory & Marketing

Labeler Name
Hikma Pharmaceuticals Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA215320
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-05-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0138
Source: PDAC
INJECTION, ACETAMINOPHEN 10 MG AND IBUPROFEN 3 MG
HCPCS Dosage 10 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0143-9150-10 identifies a specific commercial package of 10 vial in 1 carton / 100 ml in 1 vial (0143-9150-01) of Combogesic Iv, a human prescription drug labeled by Hikma Pharmaceuticals Usa Inc.. This injection is formulated for intravenous use and contains acetaminophen; ibuprofen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hikma Pharmaceuticals Usa Inc. on February 05, 2024. The current certification is valid through December 31, 2027.

How is this Hikma Pharmaceuticals Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00143915010. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0143-9150-10
11-Digit CMS (5-4-2)
00143-9150-10

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.